EVO (more) Preliminary H1 2026 results: Group revenues of approximately €300.1M and adjusted Group EBITDA of approximately -€42.7M; full H1
EVO (more) Preliminary H1 2026 results: Group revenues of approximately €300.1M and adjusted Group EBITDA of approximately -€42.7M; full H1 2026 financial results to be published on August 13, 2026, as scheduled Updated FY 2026 outlook: Group revenues now expected to be approximately €570 to 610M (€595 to 635M CER) and adjusted Group EBITDA approximately -€70 to -105M (-€60 to -90M CER), compared with previous guidance of €700-780M (€730-810M CER) for Group revenues and €0-40M (€10-50M CER) for adjusted Group EBITDA Key drivers of the updated outlook: Approximately ~40% of the revenue difference shifted to 2027 primarily due to revised phasing and milestone schedules in existing partnerships; ~45% shifted beyond Q4 2026 due to delays in strategic partnerships under negotiation; ~15% attributable to lower-than-expected sales to revenue conversion relative to previously issued guidance Positive base business momentum: Net sales in D&PD ex-strategic partnerships increased by approximately 28% year-on-year in H1 2026, reflecting improved customer Engagement and commercial execution; Just - Evotec Biologics continued to benefit from high Capacity Utilization and expansion of its.
EVO (more) Preliminary H1 2026 results: Group revenues of approximately €300.1M and adjusted Group EBITDA of approximately -€42.7M; full H1 2026 financial results to be published on August 13, 2026, as scheduled Updated FY 2026 outlook: Group revenues now expected to be approximately €570 to 610M (€595 to 635M CER) and adjusted Group EBITDA approximately -€70 to -105M (-€60 to -90M CER), compared with previous guidance of €700-780M (€730-810M CER) for Group revenues and €0-40M (€10-50M CER) for adjusted Group EBITDA Key drivers of the updated outlook: Approximately ~40% of the revenue difference shifted to 2027 primarily due to revised phasing and milestone schedules in existing partnerships; ~45% shifted beyond Q4 2026 due to delays in strategic partnerships under negotiation; ~15% attributable to lower-than-expected sales to revenue conversion relative to previously issued guidance Positive base business momentum: Net sales in D&PD ex-strategic partnerships increased by approximately 28% year-on-year in H1 2026, reflecting improved customer Engagement and commercial execution; Just - Evotec Biologics continued to benefit from high Capacity Utilization and expansion of its customer base Horizon execution on track: Transformation progressing as planned across operational excellence, Scientific leadership and commercial execution; Evotec remains on track to deliver approximately 20-30% of cost savings in 2026 as part of its previously announced target of €75M in annual run-rate savings by the end of 2027